Fig. 2From: Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cellsThe cellular uptake of nanoparticles. a FCM analysis of the intracellular of Ab@Tf-Cou6-PLGA NPs in a time-dependent manner at the dose of 0.5 mg/ml. b FCM analysis of intercellular uptake of Ab@Tf-Cou6-PLGA NPs in K562 and K562/G01 cells at various doses. c FCM analysis of cellular internalization of Ab@Tf-Cou6-PLGA NPs in K562 and K562/G01 cells after Sucrose (0.45 mM) and 4 °C treatments. d FCM analysis of the cellular uptake of Tf-targeted and non-targeted nanoparticles in CML cells. e CLSM images of K562 cells after incubation with Ab@Tf-Cou6-PLGA NPs. Scale bar, 10 μm. f Colocalization analysis of K562 cells after incubation with Ab@Tf-Cou6-PLGA NPsBack to article page